Brought to you by 
Upsher-Smith acquires the rest of neurology partner Proximagen for £187.6mm up front
11 May 2022
Executive Summary
Expanding its R&D organization, especially in the CNS area, Upsher-Smith Laboratories Inc. (generic and brand drugs across neurology, dermatology, cardiology, and women’s health) is acquiring the 84.13% of public UK biotech and business partner Proximagen Group PLC that it didn’t already own for £187.6mm ($290.8mm) up front (£3.20 per share, a 20% premium) plus earn-outs. US-based Upsher will continue operating Proximagen’s Cambridge and London facilities.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Includes Earnout
- Partial Acquisition
- Payment Includes Cash for Equity
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Upsher-Smith acquires the rest of neurology partner Proximagen for £187.6mm up front
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice